ValiRx PLC Total Voting Rights (4915X)
September 01 2020 - 1:00AM
UK Regulatory
TIDMVAL
RNS Number : 4915X
ValiRx PLC
01 September 2020
VALIRX PLC
("ValiRx", the "Company" or the "Group")
Total Voting Rights
London, UK 1 September 2020: ValiRx Plc (AIM: VAL), the clinical
stage biotechnology company today updated its total voting rights
disclosure position.
In conformity with DTR 5.6.1, the Company notifies that as at
the date of this announcement, the total number of Ordinary Shares
in issue will be 56,854,039. There are no Ordinary Shares held in
treasury. Each Ordinary Share entitles the holder to a single vote
at general meetings of the Company.
The figure of 56,854,039 Ordinary Shares may be used by
shareholders (and others with notification obligations) as the
denominator for the calculations by which they will determine
whether they are required to notify their interest in, or a change
to their interest in, the Company under the Financial Conduct
Authority's Disclosure Guidance and Transparency Rules.
As announced on 28 August 2020, application has been made to the
London Stock Exchange to admit the 250,000 new ordinary shares
resulting from the Warrant Exercise to trading on AIM. Admission of
the new ordinary shares is expected to occur on or around 3
September 2020. The new ordinary shares will rank pari passu with
the existing ordinary shares.
Following admission of the 250,000 new ordinary shares to
trading on AIM on or around 3 September 2020, the Company's total
issued share capital will comprise 57,104,039 ordinary shares of
0.1 pence each.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information please contact:
ValiRx plc Tel: +44 (0) 20 7073
2628
www.valirx.com
Suzanne Dilly Suzanne.Dilly@valirx.com
Cairn Financial Advisers LLP (Nominated Tel: +44 (0) 20 7213
Adviser) 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
Peterhouse Capital Limited (Sole Broker) Tel: +44 (0) 20 7469
Duncan Vasey / Lucy Williams / Eran Zucker 0930
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVREAFPPALAEEFA
(END) Dow Jones Newswires
September 01, 2020 02:00 ET (06:00 GMT)
Valirx (LSE:VAL)
Historical Stock Chart
From Apr 2024 to May 2024
Valirx (LSE:VAL)
Historical Stock Chart
From May 2023 to May 2024